Analysis of B19 virus contamination in plasma pools for manufacturing, by using a competitive polymerase chain reaction assay
- 18 November 2002
- journal article
- research article
- Published by Wiley in Vox Sanguinis
- Vol. 83 (4) , 324-331
- https://doi.org/10.1046/j.1423-0410.2002.00227.x
Abstract
Background and Objectives The presence of B19 virus in blood poses a risk of transmission of the virus via blood or blood products. Screening processes for manufacturing should be aimed at achieving production plasma pools with B19 virus contamination levels below 104 genome equivalents/ml (geq/ml) in order to prevent transmission of infection through plasma derivatives.Materials and Methods The suitability of a competitor plasmid as an internal analytical standard for the detection of B19 virus in plasma pools was assessed by using a competitive polymerase chain reaction (PCR) assay. Seventy‐five plasma pools, each consisting of 960 single donations, were analysed for B19 virus contamination following a lysis treatment.Results The amount of competitor plasmid in the competitive PCR assay established, with good accuracy, a threshold value for discrimination of the viral load in plasma pools. Analysis of samples from plasma pools showed that 12% of pools were contaminated with B19 virus at levels above the set threshold value.Conclusions The competitive PCR assay developed proved to be effective for discrimination of the B19 virus contamination level in screening of plasma pools for manufacturing.Keywords
This publication has 40 references indexed in Scilit:
- Large-Scale Screening for Human Parvovirus B19 DNA by PCR: Application to the Quality Control of Plasma for FractionationVox Sanguinis, 2000
- Screening of Blood Donors for Human Parvovirus B19 and Characterization of the ResultsVox Sanguinis, 1999
- Presence and Significance of Parvovirus B19 in Blood and Blood ProductsBiologicals, 1998
- Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufactureBritish Journal of Haematology, 1996
- Transmission of symptomatic parvovirus B19 infection by clotting factor concentrateBritish Journal of Haematology, 1996
- Transfusion‐transmitted human parvovirus B19 infection in a thalassemic patientTransfusion, 1995
- B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentratesThe Lancet, 1994
- Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentratesAmerican Journal of Hematology, 1992
- Transmission of Human Parvovirus B19 by Coagulation Factor ConcentratesVox Sanguinis, 1990
- TRANSMISSION OF SERUM PARVOVIRUS-LIKE VIRUS BY CLOTTING-FACTOR CONCENTRATESThe Lancet, 1983